Balchem (BCPC) 10-Q10 Nov 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2014	Nov. 07, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'BALCHEM CORP	'
Entity Central Index Key	'0000009326	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'Yes	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	30,741,994
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$25,404	$208,747
Accounts receivable, net of allowance for doubtful accounts of $289 and $115 at September 30, 2014 and December 31, 2013	72,607	39,386
Inventories	58,189	24,824
Prepaid expenses	2,488	2,580
Prepaid income taxes	949	899
Deferred income taxes	991	893
Other current assets	3,167	445
Total current assets	163,795	277,774
Property, plant and equipment, net	128,237	54,916
Goodwill	385,646	28,515
Intangible assets with finite lives, net	167,291	15,126
Other assets	3,831	541
Total assets	848,800	376,872
Current liabilities:	'	'
Trade accounts payable	20,648	12,395
Accrued expenses	17,951	10,660
Accrued compensation and other benefits	6,774	4,770
Customer deposits and other deferred revenue	0	72
Dividends payable	0	7,856
Current portion of long-term debt	35,000	0
Total current liabilities	80,373	35,753
Long-term debt	306,250	0
Deferred income taxes	79,507	5,884
Other long-term obligations	6,033	3,877
Total liabilities	472,163	45,514
Commitments and contingencies (note 14)	'	'
Stockholders' equity:	'	'
Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding	0	0
Common stock, $.0667 par value. Authorized 60,000,000 shares; 30,695,494 shares issued and outstanding at September 30, 2014 and 30,225,763 shares issued and outstanding at December 31, 2013	2,047	2,016
Additional paid-in capital	90,901	77,517
Retained earnings	285,431	251,627
Accumulated other comprehensive income	-1,742	198
Total stockholders' equity	376,637	331,358
Total liabilities and stockholders' equity	$848,800	$376,872

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Allowance for doubtful accounts	$289	$115
Stockholders' equity:	'	'
Preferred stock, par value (in dollars per share)	$25	$25
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.07	$0.07
Common stock, shares authorized (in shares)	60,000,000	60,000,000
Common stock, shares issued (in shares)	30,695,494	30,225,763
Common stock, shares outstanding (in shares)	30,695,494	30,225,763

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Earnings (unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Condensed Consolidated Statements of Earnings (unaudited) [Abstract]	'	'	'	'
Net sales	$160,490	$87,593	$378,715	$255,540
Cost of sales	116,003	63,071	278,678	181,901
Gross margin	44,487	24,522	100,037	73,639
Operating expenses:	'	'	'	'
Selling expenses	11,458	3,679	24,199	12,012
Research and development expenses	1,445	876	3,337	2,661
General and administrative expenses	6,300	2,991	17,353	9,509
Operating expenses	19,203	7,546	44,889	24,182
Earnings from operations	25,284	16,976	55,148	49,457
Other expenses (income):	'	'	'	'
Interest income	-3	-65	-62	-178
Interest expense	2,052	2	3,368	5
Other, net	26	-21	-30	25
Earnings before income tax expense	23,209	17,060	51,872	49,605
Income tax expense	8,031	5,403	18,068	15,478
Net earnings	$15,178	$11,657	$33,804	$34,127
Net earnings per common share - basic (in dollars per share)	$0.50	$0.39	$1.12	$1.16
Net earnings per common share - diluted (in dollars per share)	$0.49	$0.38	$1.09	$1.11

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Condensed Consolidated Statements of Comprehensive Income (unaudited) [Abstract]	'	'	'	'
Net earnings	$15,178	$11,657	$33,804	$34,127
Other comprehensive (loss) income, net of tax:	'	'	'	'
Net foreign currency translation adjustment	-1,739	749	-1,934	484
Net change in postretirement benefit plan, net of taxes of $1 and $-0- for the three months ended September 30, 2014 and 2013, and $3 and $1 for the nine months ended September 30, 2014 and 2013	-2	1	-6	-1
Other comprehensive (loss) income	-1,741	750	-1,940	483
Comprehensive income	$13,437	$12,407	$31,864	$34,610

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Comprehensive Income (unaudited) (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Other comprehensive (loss) income, net of tax:	'	'	'	'
Net change in postretirement benefit plan, taxes	$1	$0	$3	$1

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net earnings	$33,804	$34,127
Adjustments to reconcile net earnings to net cash provided by operating activities:	'	'
Depreciation and amortization	20,190	7,838
Stock compensation expense	3,449	2,887
Deferred income taxes	-3,788	73
Provision for doubtful accounts	239	0
Foreign currency transaction loss	84	69
Loss on sale of assets	140	0
Changes in assets and liabilities	'	'
Accounts receivable	-8,639	1,710
Inventories	-1,698	-3,965
Prepaid expenses and other current assets	1,531	1,564
Accounts payable and accrued expenses	3,681	-5,347
Income taxes	214	255
Customer deposits and other deferred revenue	-535	233
Other	569	428
Net cash provided by operating activities	49,241	39,872
Cash flows from investing activities:	'	'
Capital expenditures	-5,934	-6,644
Proceeds from sale of property, plant and equipment	0	40
Cash paid for acquisition, net of cash acquired	-566,607	0
Intangible assets acquired	-91	-218
Net cash used in investing activities	-572,632	-6,822
Cash flows from financing activities:	'	'
Proceeds from long-term debt	350,000	0
Principal payments on long-term debt	-8,750	0
Proceeds from revolving loan	50,000	0
Principal payments on revolving loan	-50,000	0
Cash paid for financing costs	-2,593	0
Repayments of short-term obligations	-89	-89
Proceeds from stock options exercised	6,608	6,742
Excess tax benefits from stock compensation	3,626	5,715
Dividends paid	-7,856	0
Purchase of treasury stock	-267	-86
Net cash provided by financing activities	340,679	12,282
Effect of exchange rate changes on cash	-631	110
(Decrease) increase in cash and cash equivalents	-183,343	45,442
Cash and cash equivalents beginning of period	208,747	144,737
Cash and cash equivalents end of period	$25,404	$190,179

CONDENSED_CONSOLIDATED_FINANCI

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	9 Months Ended
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	Sep. 30, 2014
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS [Abstract]	'
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	'
	NOTE 1 – CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

	The condensed consolidated financial statements presented herein have been prepared by the Company in accordance with the accounting policies described in its December 31, 2013 consolidated financial statements, and should be read in conjunction with the consolidated financial statements and notes, which appear in the Annual Report on Form 10-K for the year ended December 31, 2013. References in this report to the “Company” mean either Balchem Corporation or Balchem Corporation and its subsidiaries, including BCP Ingredients, Inc., Aberco, Inc., Balchem BV, Balchem Italia Srl, Performance Chemicals & Ingredients Company, SensoryEffects Powder Systems, Inc., SensoryEffects Cereal Systems, Inc., SensoryEffects Flavor Company, SensoryEffects International Sales, Inc., and SEPS Reading LLC, on a consolidated basis, as the context requires.

	In the opinion of management, the unaudited condensed consolidated financial statements furnished in this Form 10-Q include all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. All such adjustments are of a normal recurring nature. The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP” or “GAAP”) governing interim financial statements and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934 and therefore do not include some information and notes necessary to conform to annual reporting requirements. Certain prior year amounts have been reclassified to conform to current year presentation. The results of operations for the nine months ended September 30, 2014 are not necessarily indicative of the operating results expected for the full year or any interim period.

ACQUISITION_OF_PERFORMANCE_CHE

ACQUISITION OF PERFORMANCE CHEMICALS & INGREDIENTS COMPANY	9 Months Ended
ACQUISITION OF PERFORMANCE CHEMICALS & INGREDIENTS COMPANY	Sep. 30, 2014
ACQUISITION OF PERFORMANCE CHEMICALS & INGREDIENTS COMPANY [Abstract]	'
ACQUISITION OF PERFORMANCE CHEMICALS & INGREDIENTS COMPANY	'
	NOTE 2—ACQUISITION OF PERFORMANCE CHEMICALS & INGREDIENTS COMPANY

	On May 7, 2014, the Company acquired 100 percent (the “Acquisition”) of the outstanding common shares of Performance Chemicals & Ingredients Company (d/b/a SensoryEffects), a privately held supplier of customized food and ingredient systems, headquartered in St. Louis, Missouri, for a purchase price of approximately $569 million, including working capital acquired. SensoryEffects is a leader in powder, solid and liquid flavor systems, creamer and specialty emulsified powders, cereal-based products and other functional ingredient food and beverage delivery systems. The Acquisition of SensoryEffects accelerates the Company’s growth into the health and wellness markets. SensoryEffects was merged with the Company’s Food, Pharma & Nutrition segment, strengthening its market leadership position, and the segment was renamed SensoryEffects.

	The estimated goodwill of $357,131 arising from the Acquisition consists largely of expected synergies, including the combined entities experience and technical problem solving capabilities, and acquired workforce. The goodwill is assigned to the SensoryEffects segment and approximately $20,466 is expected to be tax deductible for income tax purposes.

	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed.

	Cash and cash equivalents	$	2,635
	Accounts receivable, net		25,674
	Inventories		32,000
	Property, plant and equipment, net		75,850
	Customer relationships		130,300
	Trade names		31,100
	Developed technology		3,200
	Other assets		3,955
	Indemnification asset		1,650
	Trade accounts payable		(10,427	)
	Accrued expenses		(6,326	)
	Deferred income taxes		(77,500	)
	Goodwill		357,131
	Total purchase price	$	569,242

	The estimated valuation of the fair value of tangible and intangible assets acquired and liabilities assumed are based on management’s estimates and assumptions that are subject to change. In preparing our preliminary fair value estimates of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. The purchase price and related allocation to assets acquired and liabilities assumed is preliminary pending finalizing actual working capital acquired as of the Acquisition date. Additionally, certain intangible assets are not tax deductible and the related deferred tax liabilities are preliminary pending management’s final review.

	Customer relationships are amortized over a 10-year period utilizing an accelerated method based on the estimated average customer attrition rate. Trade names and developed technology are amortized over 10 years and 5 years, respectively, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined.

	The Company is indemnified for tax liabilities prior to the Acquisition date. The indemnification asset balance increased by $129 from June 30, 2014 to September 30, 2014, as well as from May 7, 2014 to September 30, 2014.

	Transaction and integration related costs included in selling, general, and administrative expenses for the nine months ended September 30, 2014 are $3,110.

	The following unaudited pro forma information has been prepared as if the Acquisition had occurred on January 1, 2013.

		Three Months Ended					Nine Months Ended
		September 30,					September 30,

		Net Sales			Net Earnings		Net Sales		Net Earnings
	SensoryEffects actual results included in the Company’s consolidated income statement from May 7, 2014 through September 30, 2014	$	58,884		$	3,467	$	95,278	$	3,009

	2014 Supplemental pro forma combined financial information	$	160,490		$	15,502	$	462,732	$	41,985

	Basic earnings per share				$	0.51			$	1.39
	Diluted earnings per share				$	0.5			$	1.35

	2013 Supplemental pro forma combined financial information	$	138,478		$	11,332	$	402,642	$	32,558

	Basic earnings per share				$	0.38			$	1.1
	Diluted earnings per share				$	0.37			$	1.06


	2014 supplemental pro forma earnings for the three months ended September 30, 2014, exclude $494 of acquisition-related costs incurred. 2014 supplemental pro forma earnings for the nine months ended September 30, 2014, exclude $16,706 of acquisition-related costs incurred and $4,735 of nonrecurring expenses related to the fair value adjustment to acquisition-date inventory. The pro forma information presented does not purport to be indicative of the results that actually would have been attained if the SensoryEffects acquisition had occurred at the beginning of the periods presented and is not intended to be a projection of future results.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
STOCKHOLDERS' EQUITY	Sep. 30, 2014
STOCKHOLDERS' EQUITY [Abstract]	'
STOCKHOLDERS' EQUITY	'
	NOTE 3 – STOCKHOLDERS’ EQUITY

	STOCK-BASED COMPENSATION

	The Company records stock-based compensation in accordance with the provisions of ASC 718, “Compensation-Stock Compensation.” The Company’s results for the three and nine months ended September 30, 2014 and 2013 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings:

			Increase/(Decrease) for the
			Three Months Ended September 30,
			2014				2013
	Cost of sales		$	141			$	152
	Operating expenses			961				754
	Net earnings			(690	)			(556	)

			Increase/(Decrease) for theNine Months Ended September 30,
			2014				2013
	Cost of sales		$	452			$	456
	Operating expenses			2,997				2,431
	Net earnings			(2,189	)			(1,799	)

	As required by ASC 718, the Company has made an estimate of expected forfeitures based on its historical experience and is recognizing compensation cost only for those stock-based compensation awards expected to vest.

	The Company’s stock incentive plans allow for the granting of restricted stock awards and options to purchase common stock. Both incentive stock options and nonqualified stock options can be awarded under the plans. No option will be exercisable for longer than ten years after the date of grant. The Company has approved and reserved a number of shares to be issued upon exercise of the outstanding options that is adequate to cover all exercises. As of September 30, 2014, the plans had 4,072,896 shares available for future awards. Compensation expense for stock options and restricted stock awards is recognized on a straight-line basis over the vesting period, generally three years for stock options, four years for employee restricted stock awards, and four to seven years for non-employee director restricted stock awards. Certain awards provide for accelerated vesting if there is a change in control (as defined in the plans) or other qualifying events.

	Option activity for the nine months ended September 30, 2014 and 2013 is summarized below:

			Shares (000s)				Weighted Average Exercise Price							Weighted Average Remaining Contractual Term
											Aggregate Intrinsic
	For the nine months ended September 30, 2014										Value
											($000s)
	Outstanding as of December 31, 2013			1,893			$	20.94			$	71,465
	Granted			313				53.38
	Exercised			(456	)			14.49
	Forfeited			(126	)			56.03
	Outstanding as of September 30, 2014			1,624			$	26.29			$	49,192			5.6
	Exercisable as of September 30, 2014			1,220			$	20.83			$	43,583			4.6

			Shares (000s)				Weighted Average Exercise Price							Weighted Average Remaining Contractual Term
											Aggregate Intrinsic
	For the nine months ended September 30, 2013										Value
											($000s)
	Outstanding as of December 31, 2012			2,543			$	16.87			$	49,845
	Granted			175				38.58
	Exercised			(602	)			11.21
	Forfeited			(31	)			33.9
	Outstanding as of September 30, 2013			2,085			$	20.08			$	66,048			5.3
	Exercisable as of September 30, 2013			1,604			$	15.97			$	57,399			4.3

	ASC 718 requires companies to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted average assumptions: dividend yields of 0.5% and 0.5%; expected volatilities of 34% and 39%; risk-free interest rates of 1.8% and 1.0%; and expected lives of 5.6 and 5.0 years, in each case for the nine months ended September 30, 2014 and 2013, respectively.

	The Company used a projected expected life for each award granted based on historical experience of employees’ exercise behavior. Expected volatility is based on the Company’s historical volatility levels. Dividend yields are based on the Company’s historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury zero coupon issues with a remaining term equal to the expected life.

	Other information pertaining to option activity during the nine months ended September 30, 2014 and 2013 was as follows:

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2014				2013				2014			2013
	Weighted-average fair value of options granted		$	16.38			$	17.83			$	17.36		$	13.02
	Total intrinsic value of stock options exercised ($000s)		$	7,241			$	8,260			$	18,185		$	20,244

	Non-vested restricted stock activity for the nine months ended September 30, 2014 and 2013 is summarized below:

							Weighted Average Grant Date Fair Value

Nine months ended September 30, 2014	Shares (000s)
Non-vested balance as of December 31, 2013				172			$	33.69
Granted			25				51.03
Vested			(24	)			37.61
Forfeited			(6	)			45.32
Non-vested balance as of September 30, 2014			167			$	35.27

						Weighted Average Grant Date Fair Value

Nine months ended September 30, 2013		Shares (000s)
Non-vested balance as of December 31, 2012			258			$	26.88
Granted			21				38.1
Vested			(5	)			35.79
Forfeited			(24	)			31.97
Non-vested balance as of September 30, 2013			250			$	27.11

As of September 30, 2014 and 2013, there was $6,537 and $6,185, respectively, of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the plans. As of September 30, 2014, the unrecognized compensation cost is expected to be recognized over a weighted-average period of 1.6 years. The Company estimates that share-based compensation expense for the year ended December 31, 2014 will be approximately $4,600.

REPURCHASE OF COMMON STOCK

The Company has an approved stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 2,092,703 shares have been purchased, none of which remained in treasury at September 30, 2014. During the nine months ended September 30, 2014, a total of 4,969 shares have been purchased at an average cost of $53.81 per share. The Company intends to acquire shares from time to time at prevailing market prices if and to the extent it deems it advisable to do so based on its assessment of corporate cash flow, market conditions and other factors.

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2014
INVENTORIES [Abstract]	'
INVENTORIES	'
	NOTE 4 – INVENTORIES

	Inventories at September 30, 2014 and December 31, 2013 consisted of the following:

		September 30,		31-Dec-13
		2014
	Raw materials	$	23,097	$	8,454
	Work in progress		2,395		1,330
	Finished goods		32,697		15,040
	Total inventories	$	58,189	$	24,824

PROPERTY_PLANT_AND_EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	9 Months Ended
PROPERTY, PLANT AND EQUIPMENT	Sep. 30, 2014
PROPERTY, PLANT AND EQUIPMENT [Abstract]	'
PROPERTY, PLANT AND EQUIPMENT	'
	NOTE 5 – PROPERTY, PLANT AND EQUIPMENT

	Property, plant and equipment at September 30, 2014 and December 31, 2013 are summarized as follows:

		September 30,		31-Dec-13
		2014		31-Dec-13
	Land	$	3,184	$	2,054
	Building		30,838		19,732
	Equipment		149,846		86,147
	Construction in progress		5,927		1,754
			189,795		109,687
	Less: accumulated depreciation		61,558		54,771
	Property, plant and equipment, net	$	128,237	$	54,916

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	9 Months Ended
INTANGIBLE ASSETS	Sep. 30, 2014
INTANGIBLE ASSETS [Abstract]	'
INTANGIBLE ASSETS	'
	NOTE 6 – INTANGIBLE ASSETS

	The Company had goodwill in the amount of $385,646 as of September 30, 2014 and $28,515 as of December 31, 2013 subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.”

	The changes in the carrying amount of goodwill for the nine months ended September 30, 2014, are as follows:

	Goodwill at January 1, 2014	$	28,515
	Goodwill as a result of the Acquisition of Performance Chemicals & Ingredients Company – see Note 2		357,131
	Goodwill at September 30, 2014	$	385,646

	There were no changes in the carrying amount of goodwill for the three months ended September 30, 2014.

	Identifiable intangible assets with finite lives at September 30, 2014 and December 31, 2013 are summarized as follows:

				Gross				Gross
		Amortization		Carrying		Accumulated Amortization at 9/30/14		Carrying		Accumulated Amortization at 12/31/13
		Period		Amount at 9/30/14				Amount at 12/31/13
		(in years)
	Customer lists		10	$	167,442	$	35,264	$	37,142	$	24,552
	Trademarks & trade names		17-Oct		32,013		1,744		910		461
	Developed technology		5		3,200		294		-		-
	Regulatory registration costs		10-May		1,647		625		1,644		514
	Patents & trade secrets		15-17		1,651		912		1,593		849
	Other		10-May		754		577		754		541
				$	206,707	$	39,416	$	42,043	$	26,917

	Amortization of identifiable intangible assets was approximately $12,500 for the nine months ended September 30, 2014. Assuming no change in the gross carrying value of identifiable intangible assets, the estimated amortization expense for the remainder of 2014 is $7,000, approximately $26,400 for 2015, $24,200 for 2016, $20,300 for 2017, $18,000 for 2018 and $16,200 for 2019. At September 30, 2014, there were no identifiable intangible assets with indefinite useful lives as defined by ASC 350. Identifiable intangible assets are reflected in “Intangible assets with finite lives, net” in the Company’s condensed consolidated balance sheets. There were no changes to the useful lives of intangible assets subject to amortization during the nine months ended September 30, 2014.

LONGTERM_DEBT

LONG-TERM DEBT	9 Months Ended
LONG-TERM DEBT	Sep. 30, 2014
LONG-TERM DEBT [Abstract]	'
LONG-TERM DEBT	'
	NOTE 7 – LONG-TERM DEBT

	On May 7, 2014, the Company and a bank syndicate entered into a loan agreement providing for a senior secured term loan of $350,000 and revolving loan of $100,000 (collectively referred to as the “loans”). The term loan and $50,000 of the revolving loan were used to fund the Performance Chemicals & Ingredients Company acquisition (see Note 2) and for general corporate purposes. At September 30, 2014, the Company had a total of $341,250 of debt outstanding. The term loan is payable in quarterly installments of $8,750 commencing on September 30, 2014, with the outstanding principal due on the maturity date. The Company may draw on the revolving loan at its discretion and the revolving loan does not have installments and all outstanding amounts are due on the maturity date. The loans may be voluntarily prepaid in whole or in part without premium or penalty and have a maturity date of May 7, 2019. The loans are subject to an interest rate equal to LIBOR or a fluctuating rate as defined by the loan agreement, at the Company’s discretion; plus an applicable rate. The applicable rate is based upon the Company’s consolidated leverage ratio, as defined in the loan agreement, and the interest rate was 1.90% at September 30, 2014. The Company has $100,000 of undrawn revolving loan at September 30, 2014 that is subject to a commitment fee; which is based on the Company’s consolidated leverage ratio as defined in the loan agreement. The loan agreement contains quarterly covenants requiring the consolidated leverage ratio to be less than a certain maximum ratio and the consolidated fixed charge coverage ratio to exceed a certain minimum ratio. At September 30, 2014, the Company was in compliance with these covenants. Indebtedness under the Company’s loan agreements are secured by assets of the company.

	The following table summarizes the future minimum debt payments:

		2014		2015		2016		2017		2018		2019
	Current portion of long-term debt	$	8,750	$	26,250
	Long-term debt				8,750	$	35,000	$	35,000	$	35,000	$	192,500
	Total	$	8,750	$	35,000	$	35,000	$	35,000	$	35,000	$	192,500

	Costs associated with the issuance of debt instruments are capitalized and amortized over the terms of the respective financing arrangements using the effective interest method. If debt is retired early, the related unamortized costs are expensed in the period the debt is retired. Capitalized costs net of accumulated amortization total $2,299 at September 30, 2014. Amortization expense pertaining to these costs totaled $193 and $296 for the three and nine months ended September 30, 2014, respectfully, and is included in interest expense in the accompanying condensed consolidated statement of earnings.

NET_EARNINGS_PER_SHARE

NET EARNINGS PER SHARE	9 Months Ended
NET EARNINGS PER SHARE	Sep. 30, 2014
NET EARNINGS PER SHARE [Abstract]	'
NET EARNINGS PER SHARE	'
	NOTE 8 – NET EARNINGS PER SHARE

	The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share:

				Number of Shares
		Net Earnings		(Denominator)		Per Share Amount
	Three months ended September 30, 2014	(Numerator)
	Basic EPS – Net earnings and weighted average common shares outstanding	$	15,178		30,463,188	$	0.5

	Effect of dilutive securities – stock options and restricted stock				783,090

	Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	$	15,178		31,246,278	$	0.49

				Number of Shares
		Net Earnings		(Denominator)		Per Share Amount
	Three months ended September 30, 2013	(Numerator)
	Basic EPS – Net earnings and weighted average common shares outstanding	$	11,657		29,708,370	$	0.39

	Effect of dilutive securities – stock options and restricted stock				1,215,240

	Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	$	11,657		30,923,610	$	0.38

				Number of Shares
		Net Earnings		(Denominator)		Per Share Amount
	Nine months ended September 30, 2014	(Numerator)
	Basic EPS – Net earnings and weighted average common shares outstanding	$	33,804		30,296,753	$	1.12

	Effect of dilutive securities – stock options and restricted stock				839,437

	Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	$	33,804		31,136,190	$	1.09

				Number of Shares
		Net Earnings		(Denominator)		Per Share Amount
	Nine months ended September 30, 2013	(Numerator)
	Basic EPS – Net earnings and weighted average common shares outstanding	$	34,127		29,509,991	$	1.16

	Effect of dilutive securities – stock options and restricted stock				1,268,110

	Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	$	34,127		30,778,101	$	1.11

	The Company had stock options covering 184,976 and 8,800 shares at September 30, 2014 and 2013, respectively, that could potentially dilute basic earnings per share in future periods that were not included in diluted earnings per share because their effect on the period presented was anti-dilutive.

	The Company has some share-based payment awards that have non-forfeitable dividend rights. These awards are restricted shares and they participate on a one-for-one basis with holders of common stock. These awards have an immaterial impact as participating securities with regard to the calculation using the two-class method for determining earnings per share.

INCOME_TAXES

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2014
INCOME TAXES [Abstract]	'
INCOME TAXES	'
	NOTE 9 – INCOME TAXES

	The Company accounts for uncertainty in income taxes in accordance with ASC 740-10, “Accounting for Uncertainty in Income Taxes.” ASC 740-10 clarifies whether or not to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. All of the unrecognized tax benefits, if recognized in future periods, would impact the Company’s effective tax rate. The Company files income tax returns in the U.S. and in various states and foreign countries. As of September 30, 2014, in the major jurisdictions where the Company operates, it is generally no longer subject to income tax examinations by tax authorities for years before 2010. During the nine months ended September 30, 2014, the increase in the amount of unrecognized tax benefits was primarily related to the aforementioned Acquisition (See Note 2) of Performance Chemicals & Ingredients Company (d/b/a SensoryEffects). The Acquisition resulted in an assumed liability for unrecognized tax benefits based on an estimated fair value of $1,650. The Company is indemnified for this liability, and as such, has recognized a corresponding indemnification asset of $1,650. During the nine months ended September 30, 2013, there was no significant change to the amount of unrecognized tax benefits. As of September 30, 2014 and December 31, 2013, the Company had approximately $5,200 and $3,100, respectively, of unrecognized tax benefits, which are included in other long-term obligations on the Company’s consolidated balance sheets. Other than potential changes to the estimated fair value of the assumed liability for unrecognized tax benefits related to the Acquisition of Performance Chemicals & Ingredients Company, the Company does not anticipate any material change in the total amount of unrecognized tax benefits to occur within the next twelve months. The Company includes interest expense or income as well as potential penalties on unrecognized tax positions as a component of income tax expense in the consolidated statements of earnings. The total amount of accrued interest and penalties related to uncertain tax positions at September 30, 2014 and December 31, 2013 was approximately $1,550 and $1,050, respectively, and is included in other long-term obligations.

SEGMENT_INFORMATION

SEGMENT INFORMATION	9 Months Ended
SEGMENT INFORMATION	Sep. 30, 2014
SEGMENT INFORMATION [Abstract]	'
SEGMENT INFORMATION	'
	NOTE 10 – SEGMENT INFORMATION

	The Company's reportable segments are strategic businesses that offer products and services to different markets. Presently, the Company has three segments: Specialty Products; SensoryEffects; and Animal Nutrition & Health.

	Business Segment Net Sales:

		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014			2013		2014			2013
	Specialty Products	$	13,652		$	12,420	$	40,086		$	38,419
	SensoryEffects		71,821			12,348		133,170			35,502
	Animal Nutrition & Health		75,017			62,825		205,459			181,619
	Total	$	160,490		$	87,593	$	378,715		$	255,540

	Business Segment Earnings Before Income Taxes:

		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014			2013		2014			2013
	Specialty Products	$	5,306		$	4,848	$	15,576		$	15,036
	SensoryEffects		8,743			2,760		14,218			8,536
	Animal Nutrition & Health		11,729			9,368		28,696			25,885
	Transaction and integration costs		(494	)		-		(3,342	)		-
	Interest and other income (expense)		(2,075	)		84		(3,276	)		148
	Total	$	23,209		$	17,060	$	51,872		$	49,605

	Transaction and integration costs are primarily related to the definitive agreement to acquire Performance Chemicals & Ingredients Company (d/b/a SensoryEffects; see Note 2).

	The following table summarizes domestic (U.S.) and foreign sales for the three and nine months ended September 30, 2014 and September 30, 2013:

		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014			2013		2014			2013
	Domestic	$	124,088		$	60,742	$	278,422		$	173,855
	Foreign		36,402			26,851		100,293			81,685
	Total	$	160,490		$	87,593	$	378,715		$	255,540

SUPPLEMENTAL_CASH_FLOW_INFORMA

SUPPLEMENTAL CASH FLOW INFORMATION	9 Months Ended
	Sep. 30, 2014
SUPPLEMENTAL CASH FLOW INFORMATION [Abstract]	'
SUPPLEMENTAL CASH FLOW INFORMATION	'
	NOTE 11 – SUPPLEMENTAL CASH FLOW INFORMATION

	Cash paid during the nine months ended September 30, 2014 and 2013 for income taxes and interest is as follows:

		Nine Months Ended
		September 30,
			2014		2013
	Income taxes		$	17,920	$	9,274
	Interest		$	3,006	$	22

ACCUMULATED_OTHER_COMPREHENSIV

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	9 Months Ended
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	Sep. 30, 2014
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) [Abstract]	'
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	'
	NOTE 12 – ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

	The changes in accumulated other comprehensive income (loss) were as follows:

		Three Months Ended
		September 30,
		2014			2013
	Net foreign currency translation adjustment	$	(1,739	)	$	749
	Net change in postretirement benefit plan (see Note 13 for further information)
	Amortization of prior service credit		(5	)		(5	)
	Amortization of loss		2			6
	Total before tax		(3	)		1
	Tax		1			-
	Net of tax		(2	)		1

	Total other comprehensive (loss) income	$	(1,741	)	$	750

		Nine Months Ended
		September 30,
		2014			2013
	Net foreign currency translation adjustment	$	(1,934	)	$	484

	Net change in postretirement benefit plan (see Note 13 for further information)
	Amortization of prior service credit		(14	)		(14	)
	Amortization of loss		5			12
	Total before tax		(9	)		(2	)
	Tax		3			1
	Net of tax		(6	)		(1	)

	Total other comprehensive (loss) income	$	(1,940	)	$	483

EMPLOYEE_BENEFIT_PLAN

EMPLOYEE BENEFIT PLAN	9 Months Ended
EMPLOYEE BENEFIT PLAN	Sep. 30, 2014
EMPLOYEE BENEFIT PLAN [Abstract]	'
EMPLOYEE BENEFIT PLAN	'
	NOTE 13 – EMPLOYEE BENEFIT PLAN

	The Company currently provides postretirement benefits in the form of a retirement medical plan under a collective bargaining agreement covering eligible retired employees of its Verona, Missouri facility.

	Net periodic benefit costs for such retirement medical plan were as follows:

		Nine Months Ended
		September 30,
		2014			2013
	Service cost	$	43		$	51
	Interest cost		36			32
	Amortization of prior service credit		(14	)		(14	)
	Amortization of loss		5			12
	Net periodic benefit cost	$	70		$	81

	The amount recorded for this obligation on the Company’s balance sheet as of September 30, 2014 and December 31, 2013 is $1,232 and $1,152, respectively, and is included in other long-term obligations. The plan is unfunded and approved claims are paid from Company funds. Historical cash payments made under such plan have typically been less than $100 per year.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2014
COMMITMENTS AND CONTINGENCIES [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 14 – COMMITMENTS AND CONTINGENCIES

	In 2012, the Company entered into a six (6) year lease extension for approximately 20,000 square feet of office space in New Hampton, New York. The office space serves as the Company’s general offices and as a laboratory facility. In 2013, SensoryEffects entered into a three (3) year lease for approximately 40,000 square feet of warehouse space in St. Louis, Missouri. The Company leases most of its vehicles and office equipment under non-cancelable operating leases, which primarily expire at various times through 2029.

	Rent expense charged to operations under such lease agreements for the nine months ended September 30, 2014 and 2013 aggregated approximately $1,114 and $771, respectively. Aggregate future minimum rental payments required under all non-cancelable operating leases at September 30, 2014 are as follows:

	Year
	October 1, 2014 to December 31, 2014	$	476
	2015		1,813
	2016		1,424
	2017		1,177
	2018		926
	2019		447
	Thereafter		2,104
	Total minimum lease payments	$	8,367

	In 1982, the Company discovered and thereafter removed a number of buried drums containing unidentified waste material from the Company’s site in Slate Hill, New York. The Company thereafter entered into a Consent Decree to evaluate the drum site with the New York Department of Environmental Conservation (“NYDEC”) and performed a Remedial Investigation/Feasibility Study that was approved by NYDEC in February 1994. Based on NYDEC requirements, the Company cleaned the area and removed soil from the drum burial site, which was completed in 1996. The Company continues to be involved in discussions with NYDEC to evaluate test results and determine what, if any, additional actions will be required on the part of the Company to close out the remediation of this site. Additional actions, if any, would likely require the Company to continue monitoring the site. The cost of such monitoring has been less than $5 per year for the period 2004 to date.

	The Company’s Verona, Missouri facility, while held by a prior owner, was designated by the EPA as a Superfund site and placed on the National Priorities List in 1983, because of dioxin contamination on portions of the site. Remediation conducted by the prior owner under the oversight of the EPA and the Missouri Department of Natural Resources (“MDNR”) included removal of dioxin contaminated soil and equipment, capping of areas of residual contamination in four relatively small areas of the site separate from the manufacturing facilities, and the installation of wells to monitor groundwater and surface water contamination by organic chemicals. No ground water or surface water treatment was required. The Company believes that remediation of the site is complete. In 1998, the EPA certified the work on the contaminated soils to be complete. In February 2000, after the conclusion of two years of monitoring groundwater and surface water, the former owner submitted a draft third party risk assessment report to the EPA and MDNR recommending no further action. The prior owner is awaiting the response of the EPA and MDNR to the draft risk assessment.

	While the Company must maintain the integrity of the capped areas in the remediation areas on the site, the prior owner is responsible for completion of any further Superfund remedy. The Company is indemnified by the sellers under its May 2001 asset purchase agreement covering its acquisition of the Verona, Missouri facility for potential liabilities associated with the Superfund site and one of the sellers, in turn, has the benefit of certain contractual indemnification by the prior owner that is implementing the above-described Superfund remedy.

	From time to time, the Company is a party to various litigation, claims and assessments. Management believes that the ultimate outcome of such matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity.

FAIR_VALUE_OF_FINANCIAL_INSTRU

FAIR VALUE OF FINANCIAL INSTRUMENTS	9 Months Ended
FAIR VALUE OF FINANCIAL INSTRUMENTS	Sep. 30, 2014
FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract]	'
FAIR VALUE OF FINANCIAL INSTRUMENTS	'
	NOTE 15 – FAIR VALUE OF FINANCIAL INSTRUMENTS

	The Company has a number of financial instruments, none of which are held for trading purposes. The Company estimates that the fair value of all financial instruments at September 30, 2014 and December 31, 2013 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying condensed consolidated balance sheets. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessarily required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The Company’s financial instruments, principally cash equivalents, accounts receivable, accounts payable and accrued liabilities, are carried at cost which approximates fair value due to the short-term maturity of these instruments. Cash and cash equivalents at September 30, 2014 include $771 in money market funds. The money market funds are valued using level one inputs, as defined by ASC 820, “Fair Value Measurement.”

ACQUISITION_OF_PERFORMANCE_CHE1

ACQUISITION OF PERFORMANCE CHEMICALS & INGREDIENTS COMPANY (Tables)	9 Months Ended
	Sep. 30, 2014
ACQUISITION OF PERFORMANCE CHEMICALS & INGREDIENTS COMPANY [Abstract]	'
Estimated fair values of the assets acquired and liabilities assumed	'
	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed.

	Cash and cash equivalents	$	2,635
	Accounts receivable, net		25,674
	Inventories		32,000
	Property, plant and equipment, net		75,850
	Customer relationships		130,300
	Trade names		31,100
	Developed technology		3,200
	Other assets		3,955
	Indemnification asset		1,650
	Trade accounts payable		(10,427	)
	Accrued expenses		(6,326	)
	Deferred income taxes		(77,500	)
	Goodwill		357,131
	Total purchase price	$	569,242
Acquisition of unaudited pro forma information	'
	The following unaudited pro forma information has been prepared as if the Acquisition had occurred on January 1, 2013.

		Three Months Ended					Nine Months Ended
		September 30,					September 30,

		Net Sales			Net Earnings		Net Sales		Net Earnings
	SensoryEffects actual results included in the Company’s consolidated income statement from May 7, 2014 through September 30, 2014	$	58,884		$	3,467	$	95,278	$	3,009

	2014 Supplemental pro forma combined financial information	$	160,490		$	15,502	$	462,732	$	41,985

	Basic earnings per share				$	0.51			$	1.39
	Diluted earnings per share				$	0.5			$	1.35

	2013 Supplemental pro forma combined financial information	$	138,478		$	11,332	$	402,642	$	32,558

	Basic earnings per share				$	0.38			$	1.1
	Diluted earnings per share				$	0.37			$	1.06

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
STOCKHOLDERS' EQUITY (Tables)	Sep. 30, 2014
STOCKHOLDERS' EQUITY [Abstract]	'
Effect of compensation cost on earnings	'
	The Company records stock-based compensation in accordance with the provisions of ASC 718, “Compensation-Stock Compensation.” The Company’s results for the three and nine months ended September 30, 2014 and 2013 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings:

			Increase/(Decrease) for the
			Three Months Ended September 30,
			2014				2013
	Cost of sales		$	141			$	152
	Operating expenses			961				754
	Net earnings			(690	)			(556	)

			Increase/(Decrease) for theNine Months Ended September 30,
			2014				2013
	Cost of sales		$	452			$	456
	Operating expenses			2,997				2,431
	Net earnings			(2,189	)			(1,799	)
Summary of stock option activity	'
	Option activity for the nine months ended September 30, 2014 and 2013 is summarized below:

			Shares (000s)				Weighted Average Exercise Price							Weighted Average Remaining Contractual Term
											Aggregate Intrinsic
	For the nine months ended September 30, 2014										Value
											($000s)
	Outstanding as of December 31, 2013			1,893			$	20.94			$	71,465
	Granted			313				53.38
	Exercised			(456	)			14.49
	Forfeited			(126	)			56.03
	Outstanding as of September 30, 2014			1,624			$	26.29			$	49,192			5.6
	Exercisable as of September 30, 2014			1,220			$	20.83			$	43,583			4.6

			Shares (000s)				Weighted Average Exercise Price							Weighted Average Remaining Contractual Term
											Aggregate Intrinsic
	For the nine months ended September 30, 2013										Value
											($000s)
	Outstanding as of December 31, 2012			2,543			$	16.87			$	49,845
	Granted			175				38.58
	Exercised			(602	)			11.21
	Forfeited			(31	)			33.9
	Outstanding as of September 30, 2013			2,085			$	20.08			$	66,048			5.3
	Exercisable as of September 30, 2013			1,604			$	15.97			$	57,399			4.3
Other information pertaining to stock option activity	'
	Other information pertaining to option activity during the nine months ended September 30, 2014 and 2013 was as follows:

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2014				2013				2014			2013
	Weighted-average fair value of options granted		$	16.38			$	17.83			$	17.36		$	13.02
	Total intrinsic value of stock options exercised ($000s)		$	7,241			$	8,260			$	18,185		$	20,244
Non-vested restricted stock activity	'
	Non-vested restricted stock activity for the nine months ended September 30, 2014 and 2013 is summarized below:

							Weighted Average Grant Date Fair Value

	Nine months ended September 30, 2014		Shares (000s)
	Non-vested balance as of December 31, 2013			172			$	33.69
	Granted			25				51.03
	Vested			(24	)			37.61
	Forfeited			(6	)			45.32
	Non-vested balance as of September 30, 2014			167			$	35.27

							Weighted Average Grant Date Fair Value

	Nine months ended September 30, 2013		Shares (000s)
	Non-vested balance as of December 31, 2012			258			$	26.88
	Granted			21				38.1
	Vested			(5	)			35.79
	Forfeited			(24	)			31.97
	Non-vested balance as of September 30, 2013			250			$	27.11

INVENTORIES_Tables

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2014
INVENTORIES [Abstract]	'
Inventories	'
	Inventories at September 30, 2014 and December 31, 2013 consisted of the following:

		September 30,		31-Dec-13
		2014
	Raw materials	$	23,097	$	8,454
	Work in progress		2,395		1,330
	Finished goods		32,697		15,040
	Total inventories	$	58,189	$	24,824

PROPERTY_PLANT_AND_EQUIPMENT_T

PROPERTY, PLANT AND EQUIPMENT (Tables)	9 Months Ended
PROPERTY, PLANT AND EQUIPMENT (Tables)	Sep. 30, 2014
PROPERTY, PLANT AND EQUIPMENT [Abstract]	'
Property, plant and equipment	'
	Property, plant and equipment at September 30, 2014 and December 31, 2013 are summarized as follows:

		September 30,		31-Dec-13
		2014		31-Dec-13
	Land	$	3,184	$	2,054
	Building		30,838		19,732
	Equipment		149,846		86,147
	Construction in progress		5,927		1,754
			189,795		109,687
	Less: accumulated depreciation		61,558		54,771
	Property, plant and equipment, net	$	128,237	$	54,916

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	9 Months Ended
INTANGIBLE ASSETS (Tables)	Sep. 30, 2014
INTANGIBLE ASSETS [Abstract]	'
Schedule of intangible assets reconciliation of goodwill	'
	The changes in the carrying amount of goodwill for the nine months ended September 30, 2014, are as follows:

	Goodwill at January 1, 2014	$	28,515
	Goodwill as a result of the Acquisition of Performance Chemicals & Ingredients Company – see Note 2		357,131
	Goodwill at September 30, 2014	$	385,646
Intangible assets with finite lives	'
	Identifiable intangible assets with finite lives at September 30, 2014 and December 31, 2013 are summarized as follows:

				Gross				Gross
		Amortization		Carrying		Accumulated Amortization at 9/30/14		Carrying		Accumulated Amortization at 12/31/13
		Period		Amount at 9/30/14				Amount at 12/31/13
		(in years)
	Customer lists		10	$	167,442	$	35,264	$	37,142	$	24,552
	Trademarks & trade names		17-Oct		32,013		1,744		910		461
	Developed technology		5		3,200		294		-		-
	Regulatory registration costs		10-May		1,647		625		1,644		514
	Patents & trade secrets		15-17		1,651		912		1,593		849
	Other		10-May		754		577		754		541
				$	206,707	$	39,416	$	42,043	$	26,917

LONGTERM_DEBT_Tables

LONG-TERM DEBT (Tables)	9 Months Ended
LONG-TERM DEBT (Tables)	Sep. 30, 2014
LONG-TERM DEBT [Abstract]	'
Future minimum debt payments	'
	The following table summarizes the future minimum debt payments:

		2014		2015		2016		2017		2018		2019
	Current portion of long-term debt	$	8,750	$	26,250
	Long-term debt				8,750	$	35,000	$	35,000	$	35,000	$	192,500
	Total	$	8,750	$	35,000	$	35,000	$	35,000	$	35,000	$	192,500

NET_EARNINGS_PER_SHARE_Tables

NET EARNINGS PER SHARE (Tables)	9 Months Ended
NET EARNINGS PER SHARE (Tables)	Sep. 30, 2014
NET EARNINGS PER SHARE [Abstract]	'
Reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share	'
	The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share:

				Number of Shares
		Net Earnings		(Denominator)		Per Share Amount
	Three months ended September 30, 2014	(Numerator)
	Basic EPS – Net earnings and weighted average common shares outstanding	$	15,178		30,463,188	$	0.5

	Effect of dilutive securities – stock options and restricted stock				783,090

	Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	$	15,178		31,246,278	$	0.49

				Number of Shares
		Net Earnings		(Denominator)		Per Share Amount
	Three months ended September 30, 2013	(Numerator)
	Basic EPS – Net earnings and weighted average common shares outstanding	$	11,657		29,708,370	$	0.39

	Effect of dilutive securities – stock options and restricted stock				1,215,240

	Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	$	11,657		30,923,610	$	0.38

				Number of Shares
		Net Earnings		(Denominator)		Per Share Amount
	Nine months ended September 30, 2014	(Numerator)
	Basic EPS – Net earnings and weighted average common shares outstanding	$	33,804		30,296,753	$	1.12

	Effect of dilutive securities – stock options and restricted stock				839,437

	Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	$	33,804		31,136,190	$	1.09

				Number of Shares
		Net Earnings		(Denominator)		Per Share Amount
	Nine months ended September 30, 2013	(Numerator)
	Basic EPS – Net earnings and weighted average common shares outstanding	$	34,127		29,509,991	$	1.16

	Effect of dilutive securities – stock options and restricted stock				1,268,110

	Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	$	34,127		30,778,101	$	1.11

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	9 Months Ended
SEGMENT INFORMATION (Tables)	Sep. 30, 2014
SEGMENT INFORMATION [Abstract]	'
Segment reporting information, by segment	'
	Business Segment Net Sales:

		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014			2013		2014			2013
	Specialty Products	$	13,652		$	12,420	$	40,086		$	38,419
	SensoryEffects		71,821			12,348		133,170			35,502
	Animal Nutrition & Health		75,017			62,825		205,459			181,619
	Total	$	160,490		$	87,593	$	378,715		$	255,540

	Business Segment Earnings Before Income Taxes:

		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014			2013		2014			2013
	Specialty Products	$	5,306		$	4,848	$	15,576		$	15,036
	SensoryEffects		8,743			2,760		14,218			8,536
	Animal Nutrition & Health		11,729			9,368		28,696			25,885
	Transaction and integration costs		(494	)		-		(3,342	)		-
	Interest and other income (expense)		(2,075	)		84		(3,276	)		148
	Total	$	23,209		$	17,060	$	51,872		$	49,605
Geographic revenue information	'
	The following table summarizes domestic (U.S.) and foreign sales for the three and nine months ended September 30, 2014 and September 30, 2013:

		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014			2013		2014			2013
	Domestic	$	124,088		$	60,742	$	278,422		$	173,855
	Foreign		36,402			26,851		100,293			81,685
	Total	$	160,490		$	87,593	$	378,715		$	255,540

SUPPLEMENTAL_CASH_FLOW_INFORMA1

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2014
SUPPLEMENTAL CASH FLOW INFORMATION [Abstract]	'
Supplemental cash flow information	'
	Cash paid during the nine months ended September 30, 2014 and 2013 for income taxes and interest is as follows:

		Nine Months Ended
		September 30,
			2014		2013
	Income taxes		$	17,920	$	9,274
	Interest		$	3,006	$	22

ACCUMULATED_OTHER_COMPREHENSIV1

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)	9 Months Ended
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)	Sep. 30, 2014
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) [Abstract]	'
Changes in accumulated other comprehensive income (loss)	'
	The changes in accumulated other comprehensive income (loss) were as follows:

		Three Months Ended
		September 30,
		2014			2013
	Net foreign currency translation adjustment	$	(1,739	)	$	749
	Net change in postretirement benefit plan (see Note 13 for further information)
	Amortization of prior service credit		(5	)		(5	)
	Amortization of loss		2			6
	Total before tax		(3	)		1
	Tax		1			-
	Net of tax		(2	)		1

	Total other comprehensive (loss) income	$	(1,741	)	$	750

		Nine Months Ended
		September 30,
		2014			2013
	Net foreign currency translation adjustment	$	(1,934	)	$	484

	Net change in postretirement benefit plan (see Note 13 for further information)
	Amortization of prior service credit		(14	)		(14	)
	Amortization of loss		5			12
	Total before tax		(9	)		(2	)
	Tax		3			1
	Net of tax		(6	)		(1	)

	Total other comprehensive (loss) income	$	(1,940	)	$	483

EMPLOYEE_BENEFIT_PLAN_Tables

EMPLOYEE BENEFIT PLAN (Tables)	9 Months Ended
EMPLOYEE BENEFIT PLAN (Tables)	Sep. 30, 2014
EMPLOYEE BENEFIT PLAN [Abstract]	'
Components of net periodic benefit cost	'
	Net periodic benefit costs for such retirement medical plan were as follows:

		Nine Months Ended
		September 30,
		2014			2013
	Service cost	$	43		$	51
	Interest cost		36			32
	Amortization of prior service credit		(14	)		(14	)
	Amortization of loss		5			12
	Net periodic benefit cost	$	70		$	81

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
COMMITMENTS AND CONTINGENCIES (Tables)	Sep. 30, 2014
COMMITMENTS AND CONTINGENCIES [Abstract]	'
Aggregate future minimum rental payments required under non-cancelable operating leases	'
	Rent expense charged to operations under such lease agreements for the nine months ended September 30, 2014 and 2013 aggregated approximately $1,114 and $771, respectively. Aggregate future minimum rental payments required under all non-cancelable operating leases at September 30, 2014 are as follows:

	Year
	October 1, 2014 to December 31, 2014	$	476
	2015		1,813
	2016		1,424
	2017		1,177
	2018		926
	2019		447
	Thereafter		2,104
	Total minimum lease payments	$	8,367

ACQUISITION_OF_PERFORMANCE_CHE2

ACQUISITION OF PERFORMANCE CHEMICALS & INGREDIENTS COMPANY (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	7-May-14	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
			Performance Chemicals and Ingredients Company [Member]	Performance Chemicals and Ingredients Company [Member]	Performance Chemicals and Ingredients Company [Member]	Performance Chemicals and Ingredients Company [Member]	Performance Chemicals and Ingredients Company [Member]	Performance Chemicals and Ingredients Company [Member]	Performance Chemicals and Ingredients Company [Member]	Performance Chemicals and Ingredients Company [Member]	Performance Chemicals and Ingredients Company [Member]
									Customer Relationships [Member]	Trade Names [Member]	Developed Technology [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Percentage owned of the "Acquisition" (in hundredth)	'	'	100.00%	'	'	'	'	'	'	'	'
Purchase price	'	'	$569,000,000	'	'	'	'	'	'	'	'
Tax deductible for income tax purposes	'	'	20,466,000	'	'	'	'	'	'	'	'
Estimated fair values of the assets acquired and liabilities assumed [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Cash and cash equivalents	'	'	2,635,000	'	'	'	'	'	'	'	'
Accounts receivable, net	'	'	25,674,000	'	'	'	'	'	'	'	'
Inventories	'	'	32,000,000	'	'	'	'	'	'	'	'
Property, plant and equipment, net	'	'	75,850,000	'	'	'	'	'	'	'	'
Customer relationships	'	'	130,300,000	'	'	'	'	'	'	'	'
Trade names	'	'	31,100,000	'	'	'	'	'	'	'	'
Developed technology	'	'	3,200,000	'	'	'	'	'	'	'	'
Other assets	'	'	3,955,000	'	'	'	'	'	'	'	'
Indemnification asset	1,650,000	'	1,650,000	'	'	'	'	'	'	'	'
Trade accounts payable	'	'	-10,427,000	'	'	'	'	'	'	'	'
Accrued expenses	'	'	-6,326,000	'	'	'	'	'	'	'	'
Deferred income taxes	'	'	-77,500,000	'	'	'	'	'	'	'	'
Goodwill	385,646,000	28,515,000	357,131,000	'	'	'	'	'	'	'	'
Total purchase price	'	'	569,242,000	'	'	'	'	'	'	'	'
Useful life of intangible assets acquired	'	'	'	'	'	'	'	'	'10 years	'10 years	'5 years
Increase in indemnification asset balance	'	'	'	129,000	'	129,000	'	'	'	'	'
Transaction and integration related costs	'	'	'	'	'	'	3,110,000	'	'	'	'
Unaudited pro forma information [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Sensory Effects actual results included in the Company's consolidated income statement from May 7, 2014 through September 30, 2014, Net sales	'	'	'	58,884,000	'	'	95,278,000	'	'	'	'
Sensory Effects actual results included in the Company's consolidated income statement from May 7, 2014 through September 30, 2014, Net earnings	'	'	'	3,467,000	'	'	3,009,000	'	'	'	'
Supplemental pro forma combined financial information, Net Sales	'	'	'	160,490,000	138,478,000	'	462,732,000	402,642,000	'	'	'
Supplemental pro forma combined financial information, Net Earnings	'	'	'	15,502,000	11,332,000	'	41,985,000	32,558,000	'	'	'
Basic earnings per share (in dollars per share)	'	'	'	$0.51	$0.38	'	$1.39	$1.10	'	'	'
Diluted earnings per share (in dollars per share)	'	'	'	$0.50	$0.37	'	$1.35	$1.06	'	'	'
Acquisition-related costs	'	'	'	494,000	'	'	16,706,000	'	'	'	'
Non-recurring expenses related to the fair value adjustments to acquisition-date inventory	'	'	'	'	'	'	$4,735	'	'	'	'

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Shares available for future awards (in shares)	4,072,896	'	4,072,896	'
Weighted average grant date fair value [Abstract]	'	'	'	'
Unrecognized compensation cost related to non-vested shares	$6,537	$6,185	$6,537	$6,185
Weighted-average period of recognition for unrecognized compensation cost	'	'	'1 year 7 months 6 days	'
Estimated share-based compensation expense for current fiscal year	4,600	'	4,600	'
Stock splits and repurchase of common stock	'	'	'	'
Number of shares authorized to be repurchased (in shares)	3,763,038	'	3,763,038	'
Number of shares acquired under the stock repurchase plan and subsequently reissued (in shares)	'	'	2,092,703	'
Number of shares acquired under stock repurchase plan (in shares)	'	'	4,969	'
Treasury stock acquired, average cost (in dollars per share)	'	'	$53.81	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Impact of compensation cost on net earnings	-690	-556	-2,189	-1,799
Cost of Sales [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Impact of compensation cost on earnings component	141	152	452	456
Operating Expenses [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Impact of compensation cost on earnings component	961	754	2,997	2,431
Stock Options [Member]	'	'	'	'
Weighted Average Assumptions [Abstract]	'	'	'	'
Dividend yield (in hundredths)	'	'	0.50%	0.50%
Expected volatility (in hundredths)	'	'	34.00%	39.00%
Risk-free interest rate (in hundredths)	'	'	1.80%	1.00%
Expected term	'	'	'5 years 7 months 6 days	'5 years
Vesting period	'3 years	'	'	'
Stock Option Activity [Abstract]	'	'	'	'
Outstanding at beginning of period (in shares)	'	'	1,893,000	2,543,000
Granted (in shares)	'	'	313,000	175,000
Exercised (in shares)	'	'	-456,000	-602,000
Forfeited (in shares)	'	'	-126,000	-31,000
Outstanding at end of period (in shares)	1,624,000	2,085,000	1,624,000	2,085,000
Exercisable at end of period (in shares)	1,220,000	1,604,000	1,220,000	1,604,000
Weighted Average Exercise Price [Abstract]	'	'	'	'
Outstanding at beginning of period (in dollars per share)	'	'	$20.94	$16.87
Granted (in dollars per share)	'	'	$53.38	$38.58
Exercised (in dollars per share)	'	'	$14.49	$11.21
Forfeited (in dollars per share)	'	'	$56.03	$33.90
Outstanding at end of period (in dollars per share)	$26.29	$20.08	$26.29	$20.08
Exercisable, end of period (in dollars per share)	$20.83	$15.97	$20.83	$15.97
Aggregate Intrinsic Value, Outstanding, beginning of period	'	'	71,465	49,845
Aggregate Intrinsic Value, Outstanding, end of period	49,192	66,048	49,192	66,048
Aggregate Intrinsic Value, Exercisable, end of period	43,583	57,399	43,583	57,399
Weighted Average Remaining Contractual Term, Outstanding	'	'	'5 years 7 months 6 days	'5 years 3 months 18 days
Weighted Average Remaining Contractual Term, Exercisable	'	'	'4 years 7 months 6 days	'4 years 3 months 18 days
Weighted-average fair value of options granted (in dollars per share)	$16.38	$17.83	$17.36	$13.02
Total intrinsic value of stock options exercised	$7,241	$8,260	$18,185	$20,244
Restricted Stock [Member]	'	'	'	'
Non-vested restricted stock [Roll Forward]	'	'	'	'
Non-vested balance as of beginning of period (in shares)	'	'	172,000	258,000
Granted (in shares)	'	'	25,000	21,000
Vested (in shares)	'	'	-24,000	-5,000
Forfeited (in shares)	'	'	-6,000	-24,000
Non-vested balance as of end of period (in shares)	167,000	250,000	167,000	250,000
Weighted average grant date fair value [Abstract]	'	'	'	'
Non-vested balance as of beginning of period (in dollars per share)	'	'	$33.69	$26.88
Granted (in dollars per share)	'	'	$51.03	$38.10
Vested (in dollars per share)	'	'	$37.61	$35.79
Forfeited (in dollars per share)	'	'	$45.32	$31.97
Non-vested balance as of end of period (in dollars per share)	$35.27	$27.11	$35.27	$27.11
Minimum [Member] \| Restricted Stock [Member] \| Non-employee Director [Member]	'	'	'	'
Weighted Average Assumptions [Abstract]	'	'	'	'
Vesting period	'4 years	'	'	'
Maximum [Member] \| Restricted Stock [Member] \| Employee [Member]	'	'	'	'
Weighted Average Assumptions [Abstract]	'	'	'	'
Vesting period	'4 years	'	'	'
Maximum [Member] \| Restricted Stock [Member] \| Non-employee Director [Member]	'	'	'	'
Weighted Average Assumptions [Abstract]	'	'	'	'
Vesting period	'7 years	'	'	'

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
INVENTORIES [Abstract]	'	'
Raw materials	$23,097	$8,454
Work in progress	2,395	1,330
Finished goods	32,697	15,040
Total inventories	$58,189	$24,824

PROPERTY_PLANT_AND_EQUIPMENT_D

PROPERTY, PLANT AND EQUIPMENT (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$189,795	$109,687
Less: accumulated depreciation	61,558	54,771
Net property, plant and equipment	128,237	54,916
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	3,184	2,054
Building [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	30,838	19,732
Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	149,846	86,147
Construction in Progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$5,927	$1,754

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Customer Lists [Member]

Trademarks & Trade Names [Member]

Developed Technology [Member]

Regulatory Registration Costs [Member]

Patents & Trade Secrets [Member]

Other [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

INTANGIBLE ASSETS [Abstract]

Goodwill

$385,646

Goodwill [Roll Forward]

Goodwill, Beginning Balance

28,515

Goodwill as a result of the Acquisition of Performance Chemicals & Ingredients Company

357,131

Goodwill, Ending Balance

385,646

Identifiable intangible assets [Abstract]

Amortization period

'10 years

'17 years

'5 years

'10 years

'15 years

'17 years

'5 years

'10 years

Gross Carrying Amount

206,707

42,043

167,442

37,142

32,013

910

3,200

1,647

1,644

1,651

1,593

754

Accumulated Amortization

39,416

26,917

35,264

24,552

1,744

461

294

625

514

912

849

577

541

Amortization of identifiable finite-lived intangible assets [Abstract]

Changes in goodwill during period

Amortization of identifiable intangible assets

12,500

Finite-lived intangible assets, future amortization expense [Abstract]

Remainder of 2014

7,000

2015

26,400

2016

24,200

2017

20,300

2018

18,000

2019

16,200

Indefinite-lived intangible assets

LONGTERM_DEBT_Details

LONG-TERM DEBT (Details) (USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014
Debt Instrument [Line Items]	'	'
Debt outstanding	'	$341,250
Term loan quarterly payment	'	8,750
Maturity date	'	7-May-19
Term loan interest rate (in hundredth)	'	1.90%
Undrawn revolving loan	'	100,000
Maturities of Long-term Debt [Abstract]	'	'
2014	8,750	8,750
2015	35,000	35,000
2016	35,000	35,000
2017	35,000	35,000
2018	35,000	35,000
2019	192,500	192,500
Capitalized costs net of accumulated amortization	2,299	2,299
Amortization expense pertaining to Capitalized costs	193	296
Senior Secured Term Loan [Member]	'	'
Debt Instrument [Line Items]	'	'
Amount of loan	350,000	350,000
Revolving Loan [Member]	'	'
Debt Instrument [Line Items]	'	'
Amount of loan	100,000	100,000
Revolving loan used for funding of acquisition and general corporate purposes	'	50,000
Current Portion of Long-term Debt [Member]	'	'
Maturities of Long-term Debt [Abstract]	'	'
2014	8,750	8,750
2015	26,250	26,250
Long-term Debt [Member]	'	'
Maturities of Long-term Debt [Abstract]	'	'
2015	8,750	8,750
2016	35,000	35,000
2017	35,000	35,000
2018	35,000	35,000
2019	$192,500	$192,500

NET_EARNINGS_PER_SHARE_Details

NET EARNINGS PER SHARE (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net Earnings (Numerator) [Abstract]	'	'	'	'
Basic EPS - Net earnings	$15,178	$11,657	$33,804	$34,127
Diluted EPS - Net earnings	$15,178	$11,657	$33,804	$34,127
Number of Shares (Denominator) [Abstract]	'	'	'	'
Basic EPS - Weighted average common shares outstanding (in shares)	30,463,188	29,708,370	30,296,753	29,509,991
Effect of dilutive securities - stock options and restricted stock (in shares)	783,090	1,215,240	839,437	1,268,110
Diluted EPS - Weighted average common shares outstanding and effect of stock options and restricted stock (in shares)	31,246,278	30,923,610	31,136,190	30,778,101
Per Share Amount [Abstract]	'	'	'	'
Basic EPS - Net earnings (in dollars per share)	$0.50	$0.39	$1.12	$1.16
Diluted EPS - Net earnings (in dollars per share)	$0.49	$0.38	$1.09	$1.11
Stock Options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive stock options outstanding, excluded from diluted earnings per share calculation (in shares)	'	'	184,976	8,800

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
INCOME TAXES [Abstract]	'	'
Estimated fair value	$1,650	'
Indemnification asset	1,650	'
Unrecognized tax benefits	5,200	3,100
Accrued interest and penalties	$1,550	$1,050

SEGMENT_INFORMATION_Details

SEGMENT INFORMATION (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
	Sep. 30, 2014	Sep. 30, 2013	Segment	Sep. 30, 2013
SEGMENT INFORMATION [Abstract]	'	'	'	'
Number of operating segments	'	'	3	'
Segment information [Abstract]	'	'	'	'
Net sales	$160,490	$87,593	$378,715	$255,540
Earnings before income taxes	23,209	17,060	51,872	49,605
Transaction and integration costs	-494	0	-3,342	0
Interest and other income (expense)	-2,075	84	-3,276	148
Specialty Products [Member] \| Operating Segments [Member]	'	'	'	'
Segment information [Abstract]	'	'	'	'
Net sales	13,652	12,420	40,086	38,419
Earnings before income taxes	5,306	4,848	15,576	15,036
Sensory Effects [Member] \| Operating Segments [Member]	'	'	'	'
Segment information [Abstract]	'	'	'	'
Net sales	71,821	12,348	133,170	35,502
Earnings before income taxes	8,743	2,760	14,218	8,536
Animal Nutrition & Health [Member] \| Operating Segments [Member]	'	'	'	'
Segment information [Abstract]	'	'	'	'
Net sales	75,017	62,825	205,459	181,619
Earnings before income taxes	$11,729	$9,368	$28,696	$25,885

SEGMENT_INFORMATION_Revenues_F

SEGMENT INFORMATION, Revenues From External Customers and Long-Lived Assets (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Net sales	$160,490	$87,593	$378,715	$255,540
Domestic [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Net sales	124,088	60,742	278,422	173,855
Foreign [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Net sales	$36,402	$26,851	$100,293	$81,685

SUPPLEMENTAL_CASH_FLOW_INFORMA2

SUPPLEMENTAL CASH FLOW INFORMATION (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash paid during the period [Abstract]	'	'
Income taxes	$17,920	$9,274
Interest	$3,006	$22

ACCUMULATED_OTHER_COMPREHENSIV2

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Changes in accumulated other comprehensive (loss) income [Abstract]	'	'	'	'
Net foreign currency translation adjustment	($1,739)	$749	($1,934)	$484
Net change in postretirement benefit plan (see Note 13 for further information)	'	'	'	'
Amortization of prior service credit	-5	-5	-14	-14
Amortization of loss	2	6	5	12
Total before tax	-3	1	-9	-2
Tax	1	0	3	1
Net of tax	-2	1	-6	-1
Other comprehensive (loss) income	($1,741)	$750	($1,940)	$483

EMPLOYEE_BENEFIT_PLAN_Details

EMPLOYEE BENEFIT PLAN (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Components of net periodic benefit cost [Abstract]	'	'	'
Service cost	$43	$51	'
Interest cost	36	32	'
Amortization of prior service credit	-14	-14	'
Amortization of loss	5	12	'
Net periodic benefit cost	70	81	'
Amount recognized in consolidated balance sheet for benefit obligations (included in other long-term obligations)	$1,232	'	$1,152
Historical cash payments for retirement medical plan claims per year	'less than $100	'	'

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)

9 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2005

Dec. 31, 2004

sqft

Area

Seller

Operating Leased Assets [Line Items]

Operating lease term

'6 years

Office space subject to operating lease (in square feet)

20,000

Rent expense charged to operations

$1,114

$771

Future minimum rental payments required under all non-cancelable operating leases [Abstract]

October 1, 2014 to December 31, 2014

476

2015

1,813

2016

1,424

2017

1,177

2018

926

2019

447

Thereafter

2,104

Total minimum lease payments

8,367

Slate Hill, New York site [Abstract]

Annual monitoring costs, maximum

Verona, Missouri facility [Abstract]

Number of areas of the site in which capping of areas of residual contamination was performed

Monitoring period for groundwater and surface water prior to submission of risk assessment report

'2 years

Number of sellers who have the benefit of certain contractual indemnification by the prior owner

Sensory Effects [Member]

Operating Leased Assets [Line Items]

Operating lease term

'3 years

Warehouse space subject to operating lease (in square feet)

40,000

FAIR_VALUE_OF_FINANCIAL_INSTRU1

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) (Money Market Funds [Member], Level 1 [Member], USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified	Sep. 30, 2014
Money Market Funds [Member] \| Level 1 [Member]	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'
Cash and cash equivalents	$771